Parabilis Medicines, Inc. (PBLS) Key Metrics
PBLS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.81B
- Enterprise value
- $3.48B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
PBLS key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPBLS returns How much profit the business earns on the capital it uses.
PBLS financial health Debt, liquidity and how easily interest is covered.
PBLS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PBLS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PBLS cash returned to shareholders
PBLS key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Returns & profitability | ||
| Return on equity (ROE) | — | −208.9% |
| Return on invested capital (ROIC) | −489.1% | −287.5% |
| Return on assets (ROA) | −126.8% | −79.0% |
| Return on tangible assets | −180.5% | −79.0% |
| Financial health | ||
| Total debt | $58.7M | $66.2M |
| Cash & short-term investments | $27.7M | $88.0M |
| Net debt | $31.0M | −$21.8M |
| Debt / equity | — | 1.17 |
| Debt / assets | 0.73 | 0.44 |
| Current ratio | 0.52 | 2.84 |
| Quick ratio | 0.52 | 2.84 |
| Interest coverage | -99.9 | -84.9 |
| Working capital | −$27.4M | $59.8M |
| Invested capital | $14.5M | $34.7M |
| Tangible asset value | −$16.5M | $56.4M |
| Net current asset value | −$68.0M | −$606,000 |
| Capital allocation | ||
| Share buybacks (net) | $62,000 | $494,000 |
| Capex / depreciation | 0.12 | 0.42 |
| Efficiency | ||
| Receivables turnover | — | 0.00 |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | — | $360,000 |
| Average payables | $13.4M | $9.5M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from PBLS's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PBLS valuation and financial ratios
Parabilis Medicines earned a return on invested capital of −489.1% in fiscal 2025. It ended the year with $58.7 million of debt and $27.7 million in cash and short-term investments, net debt of $31.0 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks.
See the PBLS income statement, the PBLS chart for price history, or the PBLS stock overview for the latest quote and news.
PBLS key metrics FAQ
What is Parabilis Medicines's ROIC?
Parabilis Medicines's return on invested capital was −489.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Parabilis Medicines have?
Parabilis Medicines had total debt of $58.7 million at the end of fiscal 2025.
Does Parabilis Medicines buy back its shares?
Yes. Parabilis Medicines spent $0.1 million on net share repurchases in fiscal 2025.
What is Parabilis Medicines's current ratio?
Parabilis Medicines's current ratio was 0.52 at the end of fiscal 2025: current assets were 0.52 times current liabilities.